Health Canada Approval Adds Another Market but Does Not Alter Competitive or Financial Headwinds

What happened

Cytokinetics announced Health Canada approval of MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) NYHA class II-III, expanding aficamten's approved geographies beyond the U.S., China, and pending EU approval. This regulatory win adds modest ex-U.S. revenue potential via partner Bayer (which holds rights in Canada) but does not address the core challenge of unseating Bristol Myers' entrenched Camzyos in the key U.S. market, where Camzyos already generated $602M in 2024 and treated over 12,500 patients by mid-2025. The company's balance sheet remains fragile with negative equity of -$521M, net debt of ~$694M, and quarterly free cash flow burn near -$100M, while Royalty Pharma claims 4.5% of aficamten sales up to $5B and term loans require 190-200% repayment. Market expectations already assume rapid global uptake and a best-in-class profile, as reflected in the stock trading around $63 and crowded bullish positioning, making incremental regulatory approvals largely priced in. The next major catalyst is ACACIA-HCM Phase 3 data in nHCM expected Q2 2026, which will be critical for justifying the company's valuation and multi-indication platform thesis.

Implication

For existing shareholders, this approval adds another revenue stream but likely only low-single-digit millions annually near term, insufficient to offset the ~$680-700M annual opex and heavy royalty obligations. The approval reinforces the international regulatory story but should not be interpreted as evidence of superior commercial execution, as Bayer's performance in Canada will be constrained by the same Camzyos competitive dynamics seen in the U.S. The key risks remain: Myqorzo's ability to capture share from Camzyos in the U.S. launch ramp, the outcome of ACACIA-HCM in nHCM, and potential need for further dilutive financing if cash burn does not moderate. With the stock near $63 and analysts' bullish targets relying on aggressive share gains, any disappointment in launch metrics or trial results could trigger a sharp de-rating toward the bear case of $40 per share. Prudent investors should wait for concrete evidence of strong U.S. prescription trends and positive ACACIA data before considering a long position; otherwise, the thesis remains a potential short or reduce.

Thesis delta

The Health Canada approval is consistent with the base case of incremental ex-U.S. approvals and does not alter the core thesis that Cytokinetics faces a difficult competitive battle against Camzyos and a strained balance sheet. The addition of Canada via Bayer adds limited near-term revenue and does not change the bear-case probability or fair value estimates. The thesis remains a POTENTIAL SELL with conviction 4, and the next major derisking event is ACACIA-HCM data.